$4 Billion! Medtronic Makes Another Acquisition

Medtronic has completed its acquisition of CathWorks for $585 million, securing the FFRangio system—a diagnostic technology that uses standard angiographic images combined with AI to calculate fractional flow reserve. The strategic significance of this deal extends far beyond a mere battle over coronary diagnostic technology roadmaps. It marks the beginning of a deeper contest over decision-making authority in PCI procedures, where the protagonists are no longer guidewires, but lines of code.

From a Guide Wire to a Line of Code

On April 20, 2026, Medtronic announced the completion of its acquisition of CathWorks. The deal, valued at $585 million, was first agreed upon in February of this year and includes undisclosed potential milestone payments.

The core asset acquired is a system called FFRangio. Its operation is straightforward: it uses standard coronary angiography images combined with artificial intelligence and computational science to directly generate fractional flow reserve (FFR) values—without requiring additional pressure wires or pharmacological hyperemia induction.

The phrase "no need" precisely addresses a long-standing pain point in the field of coronary intervention.

Pressure wire-derived fractional flow reserve (FFR) is widely recognized as the “gold standard” for assessing the functional significance of coronary stenosis and has received Class I recommendations from multiple professional society guidelines. However, its actual utilization rate in catheterization laboratories has consistently remained below 20%. The reasons are straightforward—cumbersome guidewire manipulation, time-consuming hyperemic induction, and prolonged procedural workflow. In a catheterization laboratory operating under high workload, every additional step constitutes a burden.

Just a month before Medtronic's acquisition, the ALL-RISE study results presented at the ACC 2026 meeting provided critical evidence for FFRangio. This randomized controlled trial, involving 1,930 patients across 59 centers worldwide, showed that the incidence of the composite primary adverse cardiovascular event at one year was 6.9% in the FFRangio group and 7.1% in the pressure wire group, with a non-inferiority p-value less than 0.001. A concurrent study published in The New England Journal of Medicine also noted that FFRangio significantly reduced procedure time, radiation exposure, and contrast agent use. Ajay Kirtane, an interventional cardiologist at NewYork-Presbyterian, commented: "We not only demonstrated clinical non-inferiority, but also showed tangible workflow advantages, which could promote the broader adoption of physiological assessment."

In other words, FFRangio not only achieves this but does so faster, cheaper, and in a more patient-friendly manner.

II. Medtronic's "Diagnosis First" Logic

Medtronic’s relationship with CathWorks did not begin recently. In 2018, Medtronic invested in the company; in 2022, the two parties signed a joint commercialization agreement under which Medtronic promoted the FFRangio system in the U.S., Europe, and Japan. Four years later, Medtronic acquired CathWorks outright—a strategic path consistent with Medtronic’s prior “collaborate-then-acquire” approach in fields such as cardiac ablation and neuromodulation.

But what is truly noteworthy is the strategic intent behind the acquisition.

Medtronic's current coronary intervention product line - catheters, balloons, and stents - addresses the issue of "how to open the vessel." In contrast, FFRangio addresses the question of "whether it is necessary to open the vessel." The former is at the execution level, while the latter is at the decision-making level.

Traditionally, the business model of coronary interventional device manufacturers revolves around consumables: guidewires, balloons, and stents—each PCI procedure consumes a set of these products. Interventional cardiologists are the direct users of these devices. However, FFRangio operates on a different logic—it is a diagnostic decision-making tool designed to help physicians determine whether a lesion truly requires stenting. In this logic chain, “non-intervention” itself is also a valuable outcome.

This is precisely what makes this acquisition disruptive.

In the United States and Chinese markets, more than 1 million PCI procedures are performed each year, and there has been long-standing debate in clinical practice regarding whether a significant portion of coronary artery stenosis actually requires stent implantation. If a diagnostic technology could help doctors make the "non-activation" decision, reducing unnecessary PCI procedures, it would represent a major advancement in terms of patient safety. However, from the perspective of medical device manufacturers, this is a commercial issue that requires careful consideration.

Medtronic clearly focuses on longer-term value chains. Against the dual backdrop of precision medicine and cost control, diagnostic technologies capable of providing high-quality evidence for clinical decision-making are inherently scarce resources. Owning FFRangio enables Medtronic to intervene in the clinical decision-making process *before* surgery, securing a commanding position in both the information flow and clinical judgment. As Skip Kiil, President of Medtronic’s Cardiovascular Business, stated in the transaction announcement: “This acquisition positions Medtronic at the forefront of the digital transformation in cardiovascular care.”

From a financial perspective, Medtronic expects the transaction to have a “negligible” impact on diluted earnings per share in fiscal year 2027, becoming neutral or slightly accretive thereafter. This indicates that the company does not anticipate significant short-term profit contributions from CathWorks, but rather views the acquisition as a medium- to long-term strategic positioning—a contest for control of the “entry point” in PCI procedures.

III. The Pressure Wire Being Replaced and the Competitor Unwilling to Leave the Field

FFRangio is disrupting a market long dominated by pressure wires.

Currently, the global FFR pressure wire market is highly concentrated, with a CR5 exceeding 85%. Abbott holds the top position with a market share of over 40%, followed closely by Philips and Boston Scientific. Domestic company BeiXin Life has been rapidly catching up in recent years, achieving a market share of approximately 29.5% in 2024. The core business model of these companies is highly consistent: generating recurring revenue through single-use pressure wire consumables, with each wire priced from several thousand to tens of thousands of RMB.

FFRangio precisely cuts off this revenue chain—it does not rely on disposable consumables. This means that for hospitals with a large installed base of angiography equipment, the marginal deployment cost of FFRangio is extremely low. And once this technology is widely adopted, the market demand for pressure wires will face structural compression.

From another perspective, this acquisition also puts pressure on Abbott, Philips, and Boston Scientific. These three international giants collectively hold over 90% of the high-end share in the FFR pressure wire market, with their business models heavily reliant on the continuous sales of high-value, single-use consumables. If the "no-consumables" model of FFRangio becomes widespread, it will have a substantial impact on the pricing system and revenue structure of this mature market. Medtronic, with its global sales network, has the capability to rapidly promote the clinical adoption of FFRangio—precisely the scenario that competitors are most unwilling to see.

Interestingly, Boston Scientific, Abbott, and Philips have all made forays into the field of image-derived FFR, but most solutions still require calibration with a pressure wire or have certain limitations. FFRangio is one of the few commercial products currently available that can fully assess the entire coronary tree without the need for a wire or drugs. After the publication of the ALL-RISE study, this technological advantage has been endorsed by the highest level of evidence-based medicine.

IV. Medtronic's "Offensive Posture" in 2026: An Accelerated Pace of M&A

If the acquisition of CathWorks is viewed within Medtronic's overall actions in 2026, a clearer picture emerges—not an isolated transaction, but the beginning of a systematic acceleration.

At the January J.P. Morgan Healthcare Conference, Medtronic CEO Geoff Martha explicitly stated that the company would “ramp up” its acquisition efforts in 2026, focusing on small-to-midsize, bolt-on acquisition targets characterized by “high growth and proximity to commercialization,” with transaction values ranging from several hundred million to several billion U.S. dollars. On the same day, Medtronic announced an investment of up to $90 million in Anteris Technologies, a developer of transcatheter aortic valve replacement (TAVR) devices, acquiring rights to its DurAVR biomimetic valve technology; as a result, Medtronic holds approximately 16% to 19.99% of Anteris Technologies’ equity. This investment occurred just three months after Anteris publicly reported positive one-year clinical results for its DurAVR transcatheter aortic valve, and followed negotiations between the two parties spanning two and a half years.

In March, Medtronic acquired the neurointerventional device company Scientia Vascular for $550 million (approximately RMB 3.9 billion), with potential milestone payments. The company specializes in micro-wire and micro-catheter technologies used in neurovascular surgeries. Its products can seamlessly integrate with Medtronic's existing neurovascular portfolio, helping to build a comprehensive product suite covering hemorrhagic stroke and acute ischemic stroke.

In the same month, Medtronic completed the spin-off of its diabetes business, with MiniMed listing as an independent entity on Nasdaq. Analysts noted that the spin-off will allow Medtronic to focus more on high-growth, high-margin areas such as cardiac ablation and surgical robotics.

On April 20, Medtronic not only completed its acquisition of CathWorks but also, on the same day, led an oversubscribed $100 million Series D financing round for Pulnovo Medical, which specializes in pulmonary artery denervation systems for the treatment of pulmonary hypertension and heart failure.

The CathWorks, Scientia Vascular, and Anteris transactions share a clear common feature: all targets involve technologies that have already undergone clinical validation and are either nearing commercialization or have already achieved limited commercial sales—not early-stage conceptual technologies. This directly aligns with Martha’s statement at the J.P. Morgan conference emphasizing a “preference for bolt-on acquisitions at the pre-commercialization stage.” At the same time, Medtronic has not reduced its internal R&D investment—in fiscal year 2025, the company invested approximately $2.7 billion in R&D—indicating that acquisitions serve as “accelerators,” not substitutes for internal innovation.

Notably, since the beginning of 2026, the M&A activity among large medical technology companies has generally increased. Johnson & Johnson, Boston Scientific, and Abbott have all disclosed transactions at the hundred million dollar level. Medtronic has completed two full acquisitions and two strategic investments/participations within four months, a pace that is noticeably faster than the average of 1-2 mid-sized deals per year over the past three years.

V. The Entry of the Payer: Cost Control Logic is the Greatest Catalyst

Understanding the value of FFRangio cannot only be judged by the convenience in the catheterization lab, but also by the payment logic outside the catheterization lab.

In the United States, payers such as Medicare have recently continued tightening reimbursement policies for PCI procedures, with increasingly stringent scrutiny of inappropriate revascularization. Under China’s DRG/DIP payment reform framework, hospitals’ internal motivation to control costs has also significantly strengthened. Against this backdrop, a diagnostic technology that helps physicians make more precise decisions and reduces unnecessary stent implantation inherently possesses the attribute of “creating value for payers.”

FFRangio integrates the diagnostic process directly into the routine angiography workflow, requiring no additional consumables, no additional drugs, and no extra procedural time. This means it is not only clinically effective but also a cost-reduction method from a health economics perspective. For any healthcare system facing cost control pressures, this "low-cost, high-efficiency, and not compromising clinical outcomes" technology combination holds natural appeal.

This is also why the commercial value of FFRangio cannot be measured solely as "diagnostic software." It is fundamentally a quality control tool embedded within clinical decision-making workflows—helping systems identify cases that truly require intervention while also recognizing those that can be safely managed with conservative treatment.

VI. The Boundary Between Diagnosis and Treatment Is Becoming Blurred

Medtronic’s acquisition of CathWorks reflects a deeper trend in the medical device industry: the boundary between diagnostic and therapeutic technologies is becoming increasingly blurred. The traditional business segmentation—where Company A focuses on diagnostic equipment and Company B on therapeutic consumables—is being replaced by integrated “diagnosis + therapy” closed-loop solutions.

The underlying logic is this: whoever controls the diagnostic step holds greater influence over treatment decisions. In a healthcare system driven by evidence-based medicine and health economics, decision-making authority itself is a scarce resource. FFRangio represents precisely this kind of “decision-making asset.”

From Abbott to Philips, and from Boston Scientific to Medtronic, leading players in the coronary intervention space are undergoing a paradigm shift—from a technology race centered on “how to perform procedures,” where the protagonists were guidewires, balloons, and stents, to a decision-making race centered on “whether to perform procedures,” where the protagonists are lines of code, algorithms, and diagnostic reports.

For millions of PCI procedures performed worldwide each year, this $585 million deal may just be a small footnote in the numbers. But for the future competition dynamics of the industry, it could be a turning point — from "curing the disease" to "determining whether treatment is needed," the difference lies in AI.